MEF2B (Myocyte Enhancer Factor 2B)

MEF2B (Myocyte Enhancer Factor 2B)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2B (Myocyte Enhancer Factor 2B)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MEF2B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MEF2B (Myocyte Enhancer Factor 2B)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=MEF2B" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

MEF2B (Myocyte Enhancer Factor 2B) encodes a transcription factor belonging to the MADS (MEF2, Agamous, Deficiens, serum response factor) box family of DNA-binding proteins. Located on chromosome 19p13.11, MEF2B is a member of the myocyte-specific enhancer factor 2 (MEF2) family, which also includes [MEF2A](/genes/mef2a), [MEF2C](/genes/mef2c), and [MEF2D](/genes/mef2d) [@mef2b_ncbi]. The MEF2 family proteins are ancient and conserved regulatory factors that control diverse developmental programs, particularly in muscle and neural tissues [@potthoff2007]. While all MEF2 family members share a conserved N-terminal MADS domain that mediates DNA binding and dimerization, they exhibit distinct expression patterns and functional specializations.

MEF2B (Myocyte Enhancer Factor 2B)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2B (Myocyte Enhancer Factor 2B)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MEF2B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MEF2B (Myocyte Enhancer Factor 2B)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=MEF2B" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

MEF2B (Myocyte Enhancer Factor 2B) encodes a transcription factor belonging to the MADS (MEF2, Agamous, Deficiens, serum response factor) box family of DNA-binding proteins. Located on chromosome 19p13.11, MEF2B is a member of the myocyte-specific enhancer factor 2 (MEF2) family, which also includes [MEF2A](/genes/mef2a), [MEF2C](/genes/mef2c), and [MEF2D](/genes/mef2d) [@mef2b_ncbi]. The MEF2 family proteins are ancient and conserved regulatory factors that control diverse developmental programs, particularly in muscle and neural tissues [@potthoff2007]. While all MEF2 family members share a conserved N-terminal MADS domain that mediates DNA binding and dimerization, they exhibit distinct expression patterns and functional specializations.

MEF2B was originally characterized as a transcriptional regulator of smooth muscle genes, including the smooth muscle myosin heavy chain gene. However, subsequent research has revealed broader functions in lymphocyte development, neural tissues, and oncogenesis. The protein functions as a DNA-binding transcription activator and interacts with histone deacetylases (HDACs) to modulate gene expression programs [@mef2b_ncbi]. Unlike other MEF2 family members, MEF2B exhibits relatively restricted expression in adult tissues, with highest expression in lymphoid tissues, though it is also present in the developing brain and nervous system.

Gene Structure and Chromosomal Location

The MEF2B gene is located on chromosome 19 at position p13.11 (GRCh38 coordinates: chr19:16,200,000-16,220,000 approximately). The gene encodes a protein of approximately 365 amino acids, though multiple splice variants may exist. The genomic organization includes the characteristic MADS domain encoded in the N-terminal region, which is highly conserved across all MEF2 family members [@mef2b_ncbi].

The MADS domain (named after the founding members MCM1, Agamous, Deficiens, and Serum Response Factor) spans approximately 56 amino acids and serves dual functions: it mediates dimerization between MEF2 proteins and provides the DNA-binding interface. This domain allows MEF2B to bind to A/T-rich DNA sequences known as MEF2 response elements (MRE), which contain the consensus sequence CTA(A/T)4TAG.

Protein Structure and Function

MADS Domain Architecture

The MEF2B protein possesses the canonical MADS domain structure shared among all MEF2 family members. This domain spans amino acids 1-56 and mediates:

• Dimerization: MEF2 proteins form homodimers and heterodimers with other MEF2 family members, expanding their combinatorial diversity
• DNA binding: The MADS domain directly contacts the major groove of DNA at MEF2 response elements
• Cofactor recruitment: The domain interacts with various transcriptional coactivators and corepressors, including HDACs

Transcriptional Regulation

MEF2B functions as a DNA-binding transcription factor that can both activate and repress gene expression, depending on cellular context and interacting partners. In its default state, MEF2B functions as a transcriptional activator, binding to MEF2 response elements in the promoters and enhancers of target genes. However, recruitment of corepressor complexes, particularly class IIa histone deacetylases (HDAC4, HDAC5, HDAC7, and HDAC9), can convert MEF2B into a transcriptional repressor [@tamura2014].

The balance between activation and repression is dynamically regulated by signaling pathways. Calcium influx through NMDA receptors and voltage-gated calcium channels activates calcineurin, which dephosphorylates class IIa HDACs, promoting their nuclear export and relieving repression of MEF2 target genes. This signaling cascade is particularly important in neurons, where activity-dependent gene expression underlies synaptic plasticity and learning [@flavell2008].

Expression Patterns

Tissue Distribution

MEF2B exhibits broad but relatively specific expression patterns compared to other MEF2 family members. According to RNA-seq data from the Genotype-Tissue Expression (GTEx) project and NCBI databases [@mef2b_ncbi]:

• Highest expression: Lymphoid tissues including lymph node (RPKM 18.6) and appendix (RPKM 7.2)
• Moderate expression: Adrenal gland, small intestine, lung, stomach, kidney, and heart
• Lower expression: Brain regions, with detectable expression in cortex, hippocampus, and cerebellum

Cellular Localization

As a transcription factor, MEF2B localizes predominantly to the nucleus, where it binds to DNA response elements and interacts with cofactor complexes. The nuclear localization is mediated by a nuclear localization signal (NLS) within the MADS domain region. Post-translational modifications, particularly phosphorylation, can affect nuclear-cytoplasmic shuttling.

Role in the MEF2 Family

The MEF2 family consists of four highly conserved members (MEF2A, MEF2B, MEF2C, and MEF2D) that arose from gene duplication events early in vertebrate evolution. While all family members share the MADS domain and can bind similar DNA sequences, they have diverged in their expression patterns and functional roles:

• MEF2A: Highly expressed in muscle tissues (cardiac and skeletal muscle) and brain; implicated in cardiovascular disease and neuronal survival
• MEF2B: Expressed in lymphoid tissues and developing brain; frequently mutated in B-cell lymphomas
• MEF2C: Highest expression in brain and skeletal muscle; critical for neuronal development and synaptic plasticity
• MEF2D: Ubiquitously expressed; involved in muscle differentiation and neuronal survival

Disease Associations

B-Cell Lymphomas

The most well-established disease association for MEF2B is with B-cell lymphomas, particularly germinal center (GC)-derived lymphomas including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) [@yang2018].

Molecular Mechanisms:

• MEF2B is frequently mutated in germinal center B-cell lymphomas, with approximately 11% of DLBCL and 12% of FL tumors harboring MEF2B mutations
• Common mutation hotspots include lysine 4 (K4), tyrosine 69 (Y69), and aspartic acid 83 (D83) within the N-terminal region
• These mutations enhance transcriptional activity and protein stability, promoting oncogenic transformation
• MEF2B is a member of the BCL6 transcriptional repressor complex and regulates BCL6 expression
• Mutations can lead to deregulated expression of the oncogene BCL6, disrupting the germinal center reaction

• Diffuse large B-cell lymphoma (DLBCL): MEF2B mutations are enriched in the GCB (germinal center B-cell) subtype, often co-occurring with EZH2 and TNFRSF14 mutations
• Follicular lymphoma (FL): MEF2B mutations are found in approximately 12% of cases
• Mantle cell lymphoma (MCL): MEF2B mutations have been reported in some cases
• Ocular Adnexal MALT Lymphoma: NFAT and MEF2B signaling pathway aberrations have been described [@liu2021]

Neurological Disorders

While MEF2B is less studied in the nervous system compared to MEF2C and MEF2A, emerging evidence suggests roles in neurodevelopment and neuropsychiatric disorders:

Obsessive-Compulsive Disorder (OCD):

• A GWAS study identified SNP rs8100480 located within the MEF2BNB gene associated with obsessive-compulsive symptoms
• This suggests a potential link between MEF2B function and neuropsychiatric disease vulnerability

• The broader MEF2 family (including MEF2B) has been implicated in Alzheimer's disease pathogenesis
• MEF2 activity is dysregulated in Alzheimer's disease models, affecting neuronal survival
• MEF2 proteins may protect neurons from amyloid-beta toxicity through regulation of anti-apoptotic genes [@lin2016]

• Recent studies using Parkinson's disease models have examined MEF2 family function in dopaminergic neuron survival
• MEF2 dysregulation may contribute to neurodegeneration in PD [@park2023]

Autoimmune and Inflammatory Conditions

GWAS studies have associated MEF2B loci with N-glycosylation of immunoglobulin G, demonstrating links to autoimmune diseases and hematological cancers. Altered MEF2B function may affect immune cell development and function, potentially contributing to autoimmune susceptibility.

Therapeutic Implications

HDAC Inhibitor Therapy

The interaction between MEF2B and class IIa histone deacetylases has therapeutic implications for neurodegenerative disorders. HDAC inhibitors have been explored as potential treatments for Alzheimer's disease, Parkinson's disease, and Huntington's disease [@zhang2019]:

• HDAC inhibitors can enhance MEF2 transcriptional activity by blocking HDAC-mediated repression
• In neuronal models, HDAC inhibitor treatment promotes neuronal survival and improves cognitive function
• However, the therapeutic window is complicated by the broad activity of HDAC inhibitors

Targeting MEF2B in Lymphoma

Given the frequent MEF2B mutations in B-cell lymphomas, therapeutic strategies targeting MEF2B or its transcriptional targets are being explored:

• HDAC inhibitors may be particularly effective in lymphomas with wild-type MEF2B, as they can enhance residual MEF2 activity
• BCL6 inhibitors are being developed to target the MEF2B-BCL6 axis in germinal center lymphomas
• Understanding MEF2B mutation status may help stratify patients for targeted therapy

Interactions and Pathway Membership

Protein-Protein Interactions

MEF2B interacts with several key proteins that modulate its transcriptional activity:

• Class IIa HDACs (HDAC4, HDAC5, HDAC7, HDAC9): Corepressors that bind MEF2B and recruit repressive chromatin-modifying complexes
• p300/CBP: Transcriptional coactivators with histone acetyltransferase activity
• BCL6: MEF2B is a component of the BCL6 transcriptional repressor complex
• Other MEF2 family members: Heterodimer formation expands regulatory diversity

Signaling Pathways

MEF2B integrates signals from multiple signaling pathways:

• Calcineurin-NFAT pathway: Calcium signaling through NMDA receptors activates calcineurin, which dephosphorylates HDACs, relieving MEF2 repression
• MAPK signaling: Phosphorylation of MEF2B by p38 MAPK can modulate its transcriptional activity
• PI3K/AKT signaling: AKT phosphorylation can affect MEF2 nuclear localization and activity

Mechanistic Insights in Neurodegeneration

The broader MEF2 family has been extensively studied in the context of neurodegenerative diseases, and understanding these mechanisms provides context for MEF2B function:

Amyloid-Beta Toxicity and Neuroprotection

Studies have demonstrated that MEF2 proteins, particularly MEF2A and MEF2C, protect neurons from amyloid-beta ([Aβ](/proteins/amyloid-beta)) toxicity in Alzheimer's disease models. MEF2 activation upregulates expression of anti-apoptotic genes including Bcl-2 and Bcl-xL, while downregulating pro-apoptotic mediators. Although MEF2B's specific role in this context is less characterized, the conservation of these functions across the MEF2 family suggests similar protective mechanisms may operate [@lin2016].

Tau Pathology

The microtubule-associated protein tau, whose pathological aggregation is a hallmark of Alzheimer's disease and other tauopathies, is subject to transcriptional regulation by MEF2 family members. MEF2 activity modulates expression of tau kinases and phosphatases, potentially influencing tau phosphorylation states. Dysregulation of MEF2-mediated transcription may therefore contribute to tau pathology progression.

Synaptic Dysfunction

MEF2 proteins are critical regulators of synaptic plasticity, controlling expression of genes involved in dendritic spine formation, synapse maturation, and synaptic transmission. In neurodegenerative conditions, MEF2 dysfunction contributes to synaptic loss, a correlate of cognitive decline. The activity-dependent regulation of MEF2 through calcium signaling provides a mechanism by which neural activity maintains synaptic health [@li2020].

Neuroinflammation

Emerging evidence suggests MEF2 family members regulate inflammatory responses in glial cells. MEF2C in microglia influences cytokine production and phagocytic activity, with implications for neuroinflammation in Parkinson's disease and Alzheimer's disease. While MEF2B's role in glial cells is less established, its expression in myeloid lineages suggests potential involvement.

Interactions with Other NeuroWiki Pages

MEF2B connects to multiple pages within the NeuroWiki knowledge base:

• [MEF2A](/genes/mef2a) - Family member with overlapping functions
• [MEF2C](/genes/mef2c) - Critical family member for neural development
• [MEF2D](/genes/mef2d) - Ubiquitously expressed family member
• [CREB1](/genes/creb1) - Related transcription factor in neuronal function
• [HDAC1](/genes/hdac1) - Class I HDAC with overlapping functions
• [BCL6](/proteins/bcl6) - Transcriptional partner in lymphoma
• [Synaptic plasticity mechanisms](/mechanisms/synaptic-plasticity) - MEF2-regulated process
• [Transcriptional regulation in neurodegeneration](/transcriptional-regulation-in-neurodegeneration) - MEF2 role in disease
• [Neuronal survival pathways](/mechanisms/apoptosis-neurodegeneration) - MEF2 anti-apoptotic function
• [Diffuse large B-cell lymphoma](/diseases/dlbcl) - MEF2B-associated cancer
• [Follicular lymphoma](/diseases/follicular-lymphoma) - MEF2B-associated cancer
• [Alzheimer's disease](/diseases/alzheimers-disease) - MEF2 role in AD
• [Parkinson's disease](/diseases/parkinsons-disease) - MEF2 role in PD

MEF2B in Synaptic Plasticity

MEF2 transcription factors play crucial roles in activity-dependent synaptic plasticity. While MEF2C has been most extensively studied in this context, MEF2B likely contributes to similar mechanisms:

• Activity-dependent transcription: Neural activity triggers calcium influx through NMDA receptors, activating calcineurin which dephosphorylates HDACs, liberating MEF2 proteins to activate gene transcription
• Synaptic scaling: MEF2 regulates genes involved in homeostatic synaptic scaling, adjusting synaptic strength in response to activity changes
• Dendritic spine dynamics: MEF2 controls expression of actin regulators affecting spine morphology
• Learning and memory: MEF2 target genes include those critical for memory consolidation and retrieval

MEF2B in Epigenetic Regulation

MEF2B sits at the intersection of transcription and epigenetics:

• Chromatin remodeling: Recruitment of HDACs and HATs modulates chromatin accessibility at MEF2 target genes
• Histone acetylation: MEF2-mediated transcriptional activation often involves histone acetylation changes
• DNA methylation: MEF2 binding sites may be subject to epigenetic modifications
• Long-term gene expression: Epigenetic mechanisms allow persistent transcriptional changes underlying long-term memory

MEF2B in Cellular Stress Response

MEF2 proteins respond to various cellular stresses relevant to neurodegeneration:

• Oxidative stress: MEF2 activity is modulated by oxidative stress, affecting neuronal survival
• Endoplasmic reticulum stress: MEF2 target genes include components of the unfolded protein response
• Mitochondrial dysfunction: MEF2 regulates genes involved in mitochondrial quality control
• Neuroinflammation: MEF2 may modulate glial inflammatory responses

MEF2B in Neurodevelopmental Context

During brain development, MEF2B contributes to:

• Neural progenitor proliferation: MEF2 family members regulate cell cycle genes
• Neuronal differentiation: MEF2 activates neuronal gene programs
• Glial specification: MEF2 may influence astrocyte and oligodendrocyte development
• Circuit formation: Activity-dependent MEF2 activation refines neural connections

Summary and Future Directions

MEF2B is a member of the MADS-box transcription factor family with important roles in lymphocyte development and, to a lesser extent, neural tissues. Its frequent mutation in B-cell lymphomas makes it a significant oncogene in germinal center-derived malignancies. In the nervous system, MEF2B likely contributes to transcriptional programs underlying neuronal development and plasticity, though this role is less well-characterized than for MEF2C or MEF2A.

Evolutionary Perspective

The MEF2 family arose from gene duplication events in vertebrate evolution, with the four paralogs (MEF2A, B, C, D) emerging through whole-genome duplication. This evolutionary history explains the conservation of the MADS domain while allowing functional diversification through changes in expression patterns and protein-protein interaction domains. MEF2B's specialization in lymphoid tissues represents a case of subfunctionalization, where the ancestral developmental regulator was co-opted for immune system functions.

Developmental Biology Context

During neural development, MEF2 family members exhibit distinct expression patterns that reflect their specialized functions. MEF2B expression has been detected in neural progenitor cells, where it contributes to proliferation and differentiation decisions [@chen2021]. MEF2 proteins promote neuronal differentiation by activating neuron-specific gene programs while suppressing glial differentiation pathways. In cortical development, MEF2C is the predominant family member, but MEF2B may contribute to specific cortical layer specification. MEF2 expression in the hippocampus regulates genes important for memory consolidation.

Future Research Directions

Future research directions include:

External Links

• [NCBI Gene: MEF2B](https://www.ncbi.nlm.nih.gov/gene/100271849)
• [UniProt: MEF2B](https://www.uniprot.org/uniprot/Q9QVB5)
• [Ensembl: MEF2B](https://useast.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073754)
• [OMIM: MEF2B](https://www.omim.org/entry/600513)
• [Reactome: MEF2B pathway](https://reactome.org/PathwayBrowser/MEF2B)
• [GeneCards: MEF2B](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MEF2B)

References